KR102511444B1 - 벤조산나트륨의 다형체 형태 및 그의 용도 - Google Patents
벤조산나트륨의 다형체 형태 및 그의 용도 Download PDFInfo
- Publication number
- KR102511444B1 KR102511444B1 KR1020197014543A KR20197014543A KR102511444B1 KR 102511444 B1 KR102511444 B1 KR 102511444B1 KR 1020197014543 A KR1020197014543 A KR 1020197014543A KR 20197014543 A KR20197014543 A KR 20197014543A KR 102511444 B1 KR102511444 B1 KR 102511444B1
- Authority
- KR
- South Korea
- Prior art keywords
- sodium benzoate
- disorder
- pharmaceutical composition
- sodium
- certain embodiments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
- C07C63/04—Monocyclic monocarboxylic acids
- C07C63/06—Benzoic acid
- C07C63/08—Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662412160P | 2016-10-24 | 2016-10-24 | |
| US62/412,160 | 2016-10-24 | ||
| US15/452,137 US10336679B2 (en) | 2016-10-24 | 2017-03-07 | Polymorphic forms of sodium benzoate and uses thereof |
| US15/452,137 | 2017-03-07 | ||
| PCT/CN2017/107436 WO2018077157A1 (en) | 2016-10-24 | 2017-10-24 | Polymorphic forms of sodium benzoate and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190077003A KR20190077003A (ko) | 2019-07-02 |
| KR102511444B1 true KR102511444B1 (ko) | 2023-03-16 |
Family
ID=61970963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197014543A Active KR102511444B1 (ko) | 2016-10-24 | 2017-10-24 | 벤조산나트륨의 다형체 형태 및 그의 용도 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10336679B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3529229B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7141124B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102511444B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN110167909B (cg-RX-API-DMAC7.html) |
| CA (1) | CA3041389A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL266210B (cg-RX-API-DMAC7.html) |
| MX (1) | MX2019004734A (cg-RX-API-DMAC7.html) |
| TW (5) | TWI784662B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018077157A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017215593A1 (en) | 2016-06-13 | 2017-12-21 | Syneurx International (Taiwan) Corp. | Co-crystals of sodium benzoate and uses thereof |
| US10098861B1 (en) | 2017-10-24 | 2018-10-16 | Syneurx International (Taiwan) Corp. | Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof |
| AU2018371628B2 (en) | 2017-11-22 | 2021-08-12 | Excelsior Pharmatech Labs | Benzoic acid or a salt and derivative thereof for use in preventing or treating depression |
| CN112236138B (zh) | 2017-12-05 | 2024-05-31 | 赛诺维信制药公司 | 晶体形式及其制备方法 |
| AU2018379992B2 (en) | 2017-12-05 | 2022-07-21 | Sunovion Pharmaceuticals Inc. | Nonracemic mixtures and uses thereof |
| MX2020010284A (es) | 2018-03-30 | 2021-02-18 | India Globalization Capital Inc | Método y composición para el tratamiento de los trastornos del snc. |
| US20210186937A1 (en) * | 2018-05-22 | 2021-06-24 | Duke University | Compositions and methods for treating neurodegenerative disorders with rifaximin |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| US20220304962A1 (en) * | 2019-04-24 | 2022-09-29 | Syneurx International (Taiwan) Corp. | Polymorphic forms of sodium benzoate and uses thereof |
| CA3142355A1 (en) | 2019-06-04 | 2020-12-10 | Sunovion Pharmaceuticals Inc. | Modified release formulations and uses thereof |
| WO2021245697A1 (en) | 2020-06-01 | 2021-12-09 | Celagenex Research (India) Pvt. Ltd. | Novel synergistic medicinal compositions for treating dysfunctional d-serine signaling |
| US20260041657A1 (en) * | 2024-08-09 | 2026-02-12 | Hsien-Yuan Lane | Benzoate for use in preventing or treating cognitive dysfunction |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010085452A1 (en) | 2009-01-20 | 2010-07-29 | Los Angeles Biomedical Research Institute At Harbor - Ucla Medical Center | Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical |
| US20160008476A1 (en) | 2007-10-31 | 2016-01-14 | Sk Biopharmaceuticals Co., Ltd. | Stabilized pediatric suspension of carisbamate |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3498989A (en) | 1969-04-16 | 1970-03-03 | American Home Prod | Certain 8-substituted-2-alkyl-3-benzoyl esters of ecgonine and derivatives thereof |
| US3870715A (en) | 1972-03-09 | 1975-03-11 | Nikolaus R Hansl | Substituted amino ethyl meta benzoic acid esters |
| US4041174A (en) | 1974-08-16 | 1977-08-09 | Rom-Amer Pharmaceuticals, Ltd. | Method of treating depression |
| US6150354A (en) | 1987-01-15 | 2000-11-21 | Bonnie Davis | Compounds for the treatment of Alzheimer's disease |
| GB8819494D0 (en) | 1988-08-16 | 1988-09-21 | Ucb Sa | Use of 2-amino-4-morpholino-6-propyl-1 3 5-triazines for preparation of psychotropic medicaments |
| US6746678B1 (en) | 1991-02-22 | 2004-06-08 | Howard K. Shapiro | Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments |
| US5198217A (en) * | 1991-09-24 | 1993-03-30 | Choice Pharmaceuticals | Topical demulcent for viral and inflammatory diseases of the skin |
| FR2700117B1 (fr) | 1993-01-07 | 1995-02-03 | Rhone Poulenc Rorer Sa | Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens. |
| DE4340273A1 (de) | 1993-11-26 | 1995-06-01 | Karla Dr Lehmann | Arzneimittel zur Prophylaxe des Morbus Alzheimer und zur Verhütung des Fortschreitens dieser Erkrankung |
| US5453425A (en) | 1994-07-11 | 1995-09-26 | Janssen Pharmaceutica N.V. | Risperidone oral formulation |
| ZA977967B (en) * | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
| US6255089B1 (en) * | 1997-02-27 | 2001-07-03 | Albany Medical College | Constitutively activated serotonin receptors |
| IN191496B (cg-RX-API-DMAC7.html) | 1999-07-30 | 2003-12-06 | Ranbaxy Lab Ltd | |
| US6362226B2 (en) * | 1999-12-08 | 2002-03-26 | Vanderbilt University | Modulation of in vivo glutamine and glycine levels in the treatment of autism |
| US20030185754A1 (en) | 2001-01-16 | 2003-10-02 | Genset, S.A. | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists |
| CA2433866A1 (en) | 2001-01-16 | 2002-08-29 | Genset S.A. | Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists |
| GB2383042A (en) | 2001-10-18 | 2003-06-18 | Cipla Ltd | Amorphous alendronate sodium |
| US7053122B2 (en) | 2002-08-09 | 2006-05-30 | Pfizer Inc | Therapeutic use of aryl amino acid derivatives |
| US7273889B2 (en) | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
| CN100339070C (zh) | 2002-10-24 | 2007-09-26 | 莫茨药物股份两合公司 | 包含1-氨基环己烷衍生物类和乙酰胆碱酯酶抑制剂类的药物组合物 |
| WO2004065348A1 (en) | 2003-01-23 | 2004-08-05 | Pfizer Products Inc. | Pharmaceutically acceptable salts of sertraline and pharmaceutical compositions thereof |
| JP2006526635A (ja) | 2003-06-02 | 2006-11-24 | サマリタン,ファーマスーティカルス,インク. | 血清中コルチゾール量を調節する方法および組成物 |
| ZA200605384B (en) | 2003-12-29 | 2007-10-31 | Sepracor Inc | Benzo[D]isoxazol-3-OL DAAO inhibitors |
| ATE504588T1 (de) | 2004-01-27 | 2011-04-15 | Synthon Bv | Stabile salze von olanzapin |
| BRPI0509592A (pt) | 2004-05-06 | 2007-09-25 | Cydex Inc | formulações de sabor mascarado, contendo sertralina e ciclodextrina de éter de sulfoalquila |
| WO2006096439A2 (en) | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases |
| WO2006129160A2 (en) | 2005-06-01 | 2006-12-07 | Aurobindo Pharma Limited | Stable aqueous oral solution of risperidone |
| US20110045065A1 (en) | 2005-07-11 | 2011-02-24 | Ashok Vasantray Vyas | Substance having antioxidant, geroprotective and anti-ischemic activity and method for the preparation thereof |
| US7811604B1 (en) | 2005-11-14 | 2010-10-12 | Barr Laboratories, Inc. | Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same |
| GB0603181D0 (en) | 2006-02-17 | 2006-03-29 | Merck Sharp & Dohme | Treatment of neurodegenerative and psychiatric diseases |
| US20080045512A1 (en) | 2006-08-09 | 2008-02-21 | Pfizer Inc. | Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]-pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane |
| WO2008034087A2 (en) | 2006-09-15 | 2008-03-20 | Xenoport, Inc. | Treating schizophrenia with combinations of levodopa and an antipsychotic agent |
| DE212014000063U1 (de) * | 2014-03-24 | 2015-10-12 | China Medical University | Verwendung von Benzoesäuresalz bei der Herstellung einer Zusammensetzung zur Prävention oder Behandlung von Demenz oder leichter kognitiver Beeinträchtigung |
| US10064833B2 (en) | 2016-08-04 | 2018-09-04 | Syneurx International (Taiwan) Corp. | Compositions containing benzoate compound and tannic acid for treating central nervous system disorders |
| US10098861B1 (en) * | 2017-10-24 | 2018-10-16 | Syneurx International (Taiwan) Corp. | Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof |
-
2017
- 2017-03-07 US US15/452,137 patent/US10336679B2/en active Active
- 2017-10-24 EP EP17865685.6A patent/EP3529229B1/en active Active
- 2017-10-24 KR KR1020197014543A patent/KR102511444B1/ko active Active
- 2017-10-24 TW TW110129733A patent/TWI784662B/zh active
- 2017-10-24 CA CA3041389A patent/CA3041389A1/en not_active Abandoned
- 2017-10-24 CN CN201780072982.7A patent/CN110167909B/zh active Active
- 2017-10-24 JP JP2019521650A patent/JP7141124B2/ja active Active
- 2017-10-24 TW TW110129735A patent/TWI781723B/zh not_active IP Right Cessation
- 2017-10-24 TW TW110129734A patent/TWI784663B/zh active
- 2017-10-24 WO PCT/CN2017/107436 patent/WO2018077157A1/en not_active Ceased
- 2017-10-24 TW TW106136543A patent/TWI739938B/zh active
- 2017-10-24 MX MX2019004734A patent/MX2019004734A/es unknown
- 2017-10-24 TW TW110129732A patent/TWI803935B/zh active
-
2019
- 2019-04-23 IL IL266210A patent/IL266210B/en unknown
-
2022
- 2022-04-13 IL IL292244A patent/IL292244A/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160008476A1 (en) | 2007-10-31 | 2016-01-14 | Sk Biopharmaceuticals Co., Ltd. | Stabilized pediatric suspension of carisbamate |
| WO2010085452A1 (en) | 2009-01-20 | 2010-07-29 | Los Angeles Biomedical Research Institute At Harbor - Ucla Medical Center | Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical |
| JP2012515720A (ja) * | 2009-01-20 | 2012-07-12 | ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー− ユーシーエルエー メディカル センター | 向精神薬の働きを向上させるソルビン酸、安息香酸及びその誘導体 |
Non-Patent Citations (6)
| Title |
|---|
| CHRISTIAN BUTTERHOF et al, "Co-crystallisation of benzoic acid with sodium benzoate: the significance of stoichiometry", CRYSTENGCOMM, 2012.01.01., Vol.14, No.11, pp.3945 |
| CHRISTIAN BUTTERHOF et al, ZEITSCHRIFT FUR ANORGANISCHE UND ALLGEMEINE CHEMIE, 2013.10.07., Vol.639, No.15, pp.2816-2821 |
| FANG Liang, Pharmaceutics, China Medical Science and Technology Press, 2016.03.31., pp.49-50 |
| Howard et al, Crystal Growth and Design, 2009, Vol.9, No.9, pp.3964-3975* |
| HSIEN-YUAN LANE et al, "Add-on Treatment of Benzoate for Schizophrenia: -Amino Acid Oxidase inhibitor", 2013.10.02., Vol.70, No.12, pp.1267-1275 |
| LIN, Yubin et al, "Synthesis and Purification of Sodium Benzoate", Shandong Science, 1991.03.31., Vol.4, No.1, pp.68-69 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3041389A1 (en) | 2018-05-03 |
| MX2019004734A (es) | 2019-09-26 |
| TWI803935B (zh) | 2023-06-01 |
| KR20190077003A (ko) | 2019-07-02 |
| JP2019532968A (ja) | 2019-11-14 |
| TWI784662B (zh) | 2022-11-21 |
| CN110167909B (zh) | 2023-09-19 |
| RU2019113765A3 (cg-RX-API-DMAC7.html) | 2021-06-25 |
| RU2019113765A (ru) | 2020-11-24 |
| JP7141124B2 (ja) | 2022-09-22 |
| TW202144317A (zh) | 2021-12-01 |
| TW202144316A (zh) | 2021-12-01 |
| TW202146369A (zh) | 2021-12-16 |
| TWI781723B (zh) | 2022-10-21 |
| TW201829365A (zh) | 2018-08-16 |
| EP3529229A1 (en) | 2019-08-28 |
| TWI739938B (zh) | 2021-09-21 |
| IL266210A (en) | 2019-06-30 |
| TWI784663B (zh) | 2022-11-21 |
| EP3529229B1 (en) | 2024-04-17 |
| WO2018077157A1 (en) | 2018-05-03 |
| TW202144315A (zh) | 2021-12-01 |
| IL292244A (en) | 2022-06-01 |
| US20180346400A9 (en) | 2018-12-06 |
| US10336679B2 (en) | 2019-07-02 |
| CN110167909A (zh) | 2019-08-23 |
| IL266210B (en) | 2022-06-01 |
| US20180111891A1 (en) | 2018-04-26 |
| EP3529229A4 (en) | 2020-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7141124B2 (ja) | 安息香酸ナトリウムの多形体およびその利用 | |
| TWI784198B (zh) | 環絲胺酸化合物之鹽類及其應用 | |
| WO2008065796A1 (en) | α-GLUCOSIDASE INHIBITOR | |
| US11369579B2 (en) | Polymorphic forms of sodium benzoate and uses thereof | |
| US10098861B1 (en) | Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof | |
| US20220304962A1 (en) | Polymorphic forms of sodium benzoate and uses thereof | |
| RU2782627C2 (ru) | Полиморфные формы бензоата натрия и их применения | |
| US20230218623A1 (en) | Salts of neuroceuticals and uses thereof | |
| KR102024361B1 (ko) | 벤젠 디아민 유도체를 포함하는 퇴행성 뇌질환 예방 또는 치료용 조성물 | |
| KR102399374B1 (ko) | 알츠하이머병의 치료를 위한 n-[2-(6-플루오로-1h-인돌-3-일)에틸]-3-(2,2,3,3-테트라플루오로프로폭시)벤질아민 히드로클로라이드의 신규한 다형체 형태 | |
| KR20260066411A (ko) | 신규한 트라이아졸로피리미딘 유도체 및 이의 용도 | |
| KR20180054955A (ko) | 흡습성이 개선된 글리세릴 포스포릴 콜린을 포함하는 고형 제제, 이의 용도 또는 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-4-4-P10-P22-nap-X000 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-5-5-R10-R11-asn-PN2301 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PN2301 | Change of applicant |
St.27 status event code: A-5-5-R10-R14-asn-PN2301 |
|
| R14 | Transfer of ownership recorded |
Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R14-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE) |